HealthInvest is back to showcase some of Australia’s most promising health and life sciences companies to an audience of professional and retail investors.
Morgans, IR Department, and Stockhead have once again partnered to bring together five innovative healthcare companies, offering investors a unique opportunity to discover the latest breakthroughs shaping the future of healthcare and life sciences investment.
Presenting companies and speakers include:
- Cogstate (ASX:CGS) – Brad O’Connor, CEO and Managing Director
- EBR Systems (ASX:EBR) – John McCutcheon, CEO and President
- Neurizon (ASX:NUZ) – Dr Michael Thurn, CEO and Managing Director
- Tetratherix (ASX:TTX) – Will Knox, CEO and Executive Director
Brent became CEO and Managing Director of Clever Culture Systems in 2016 and is a major shareholder. He brings a global, big-company vision and is strongly backing the company’s growth potential. Brent has led the successful transition of its flagship AI and machine vision technology, APAS®, from invention to commercialisation.
Previously, Brent spent 11 years at Cochlear Limited (ASX:COH) as a Senior Executive, overseeing a broad range of global operational and strategic functions.
Brad O’Connor, CEO of Cogstate since 2005, has led the company’s rise as a global leader in digital cognitive assessment for clinical trials and healthcare. Under his leadership, Cogstate delivered record FY25 revenue of US$53.1 million, strong profit growth, and declared its first dividend. The company’s scalable tech platform, operational focus, and partnerships have driven expansion and secured major roles in CNS research, including pivotal Alzheimer’s and neuroscience trials. Cogstate remains well-positioned for ongoing innovation and market growth.
Mr. McCutcheon has over 40 years of sales, marketing, and general management experience in medical devices. McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson).
Dr Michael Thurn brings broad experience in drug discovery, development, regulation and commercialisation, acquired through leadership roles in research organisations and industry. His previous responsibilities have included leading a variety of US Food and Drug Administration (FDA) lnvestigational New Drug (IND) applications across a range of therapeutic areas and evaluation of drugs and vaccines as part of the Therapeutic Goods Administration (TGA).
Michael has also been responsible for the execution of Phase 1 and 2 clinical trials and business development activities. He possesses strong entrepreneurial, leadership and management skills that have seen him achieve outstanding results over a 25 year career in the biotechnology industry.
As CEO, Will owns and drives the strategy that defines and delivers the Tetratherix mission, vision and culture. Including the successful acquisition of a company he founded in 2013, Will’s prior global success in the commercialisation of life-changing biomed innovations has helped Tetratherix become a contemporary biomedical platform with big ambitions.
Join us at our HealthInvest summit on Wednesday, 24th September 2025.
Whether you're a professional or retail investor, we invite you to attend HealthInvest and gain valuable insights into the cutting-edge innovations transforming the healthcare landscape.
If you'd like to be part of this exciting event, click the button below:
